PDS Biotechnology Corporation (PDSB)
| Market Cap | 73.92M +61.3% |
| Revenue (ttm) | n/a |
| Net Income | -33.67M |
| EPS | -0.64 |
| Shares Out | 72.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,860,200 |
| Open | 1.045 |
| Previous Close | 1.030 |
| Day's Range | 0.980 - 1.050 |
| 52-Week Range | 0.195 - 1.790 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 4.50 (+341.18%) |
| Est. Earnings | Nov 24, 2026 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price target is $4.5, which is an increase of 341.18% from the latest price.
News
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
PRINCETON, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted ...
PDS Biotechnology price target raised to $4 from $3 at B. Riley
B. Riley raised the firm’s price target on PDS Biotechnology (PDSB) to $4 from $3 and keeps a Buy rating on the shares. PDS Biotechnology’s PDS0301 liver-metastatic colorectal cancer data…
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Co...
PDS Biotechnology Transcript: KOL event
PDS0301 plus HAIP showed more durable responses in sequential, nonrandomized cohorts of heavily pretreated metastatic CRC patients. Management is preparing a Phase III trial, targeting a start around Q1 2027.
PDS Biotechnology registers to sell 16.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 16.5M shares of common stock. The company is not selling any…
PDS Biotechnology Registration statement: Registration filing
PDS Biotechnology filed a registration statement on October 14, 2026, providing details about a securities offering with the SEC.
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the imm...
PDS announces publication of results from Phase 2 trial of PDS0101
PDS Biotechnology (PDSB) announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, is...
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing part...
PDS Biotechnology Slides: Corporate presentation
PDS Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on September 21, 2026.
PDS Biotechnology announces initial closing of up to $22.3M PIPE financing
PDS Biotechnology (PDSB) announced the initial closing of the company’s Private Investment in Public Equity transaction. The round was led by Nant Capital, LLC with additional participation by current...
PDS Biotechnology names Soon-Shiong, James Banaag to board of directors
Effective as of the Initial Closing, Dr. Soon-Shiong and James Banaag, who currently serves the as chief financial officer of NantBio, Inc., will join the company’s board of directors. Published…
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (N...
PDS Biotechnology price target lowered to $5 from $7 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on PDS Biotechnology (PDSB) to $5 from $7 and keeps a Buy rating on the shares. The Nant-led financing is a meaningful positive…
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS B...
PDS Biotechnology reports Q2 EPS (18c), consensus (13c)
The company said, “The Company’s cash balance as of June 30, 2026, was $5.6 million.”
PDS Biotechnology price target lowered to $7 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on PDS Biotechnology (PDSB) to $7 from $15 and keeps a Buy rating on the shares. The company’s strategic shift was unexpected but…
PDS Biotech Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted ...
PDS Biotechnology Earnings release: Q2 2026
PDS Biotechnology released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
PDS Biotechnology Quarterly report: Q2 2026
PDS Biotechnology has published its Q2 2026 quarterly earnings report on August 13, 2026.
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immu...
PDS Biotechnology Transcript: AGM 2026
The 2026 annual meeting was held virtually, covering director elections, governance amendments, auditor ratification, and executive compensation. All proposals passed, a quorum was confirmed, and no shareholder questions were raised. Forward-looking risks were acknowledged.
PDS Biotechnology registers to sell 13.32M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 13.32M shares of common stock. The company is not selling any…
PDS Biotechnology Registration statement: Registration filing
PDS Biotechnology filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
PDS Biotechnology Proxy statement: Proxy filing
PDS Biotechnology filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.